One current example of this is Nr4a1, which has been proposed as a possible drug target for SNRPN-related neurodevelopment disorders, including Prader-Willi syndrome and ASD (H. Li et al. 2016) and is already under consideration as a drug target in cancer (Hedrick et al. 2015; S. O. Lee et al. 2014). Here, NR4A1 is linked to Prader-Willi syndrome.